Lanreotide is a synthetic peptide built to mimic the natural hormone somatostatin. FDA first approved it in 2007, and its label now covers acromegaly, certain neuroendocrine tumors and carcinoid syndrome. This guide summarizes its structure, label, key trials and status, using sources checked on November 17, 2026.
Quick answer: Lanreotide is a prescription peptide drug. Its label approves it for acromegaly, certain gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and carcinoid syndrome in adults. It binds somatostatin receptors, mainly subtypes 2 and 5. The label’s most common side effects are digestive symptoms, gallstones and local site reactions.
Vitrapep does not sell lanreotide; this page is a reference summary of published research and regulatory information. It is not medical advice.
What is lanreotide?
Lanreotide is a short synthetic peptide. The FDA label calls it “a synthetic cyclical octapeptide analog of the natural hormone, somatostatin” (Somatuline Depot label, 2024). It has eight amino acids. A disulfide bond between two cysteines closes the chain into a ring.
The label’s chemical name shows two D-amino acids, D-2-naphthylalanine and D-tryptophan. The chain ends in threoninamide. PubChem lists the formula C54H69N11O10S2 and a molecular weight of 1096.3 g/mol (PubChem CID 6918011). The label gives 1096.34 for the base.
The first approved product was Somatuline Depot from Ipsen. Drugs@FDA lists its original approval on August 30, 2007, as a new molecular entity with orphan status (Drugs@FDA, NDA 022074). FDA first approved lanreotide in 2007 as Somatuline Depot. For background on this family, see our overview of peptide hormones.
Lanreotide: key facts
| Fact | Detail |
|---|---|
| Structure | Cyclic peptide of eight amino acids, closed by a disulfide bond |
| Class | Somatostatin analog |
| Molecular formula | C54H69N11O10S2 (PubChem) |
| Molecular weight | 1096.3 g/mol (PubChem) |
| First FDA approval | August 30, 2007 (Somatuline Depot) |
| Approved brands | Somatuline Depot; generic lanreotide acetate products are also listed |
How does lanreotide work?
The label states that its mechanism “is believed to be similar to that of natural somatostatin.” Somatostatin is a hormone that holds back the release of other hormones.
Lanreotide binds human somatostatin receptor subtypes 2 and 5 with high affinity. It binds subtypes 1, 3 and 4 less strongly. The label names activity at subtypes 2 and 5 as the main reason it lowers growth hormone (GH).
Its primary measured effect is a fall in GH and insulin-like growth factor 1 (IGF-1). Both are raised in acromegaly. The label adds that lanreotide inhibits insulin and glucagon secretion and lowers prolactin. Like somatostatin, it acts on many endocrine, exocrine and paracrine functions. This broad action explains several label warnings, including changes in blood sugar.
What is lanreotide approved for?
Section 1 of the Somatuline Depot label lists three indications. FDA added the second and third through supplements to the original application.
- Acromegaly (2007): “long-term treatment of acromegalic patients” with an inadequate response to surgery and/or radiotherapy. It also covers patients for whom those options are not possible.
- GEP-NETs (December 16, 2014): adults with unresectable, well or moderately differentiated, locally advanced or metastatic GEP-NETs, “to improve progression-free survival” (FDA letter, 2014).
- Carcinoid syndrome (September 15, 2017): adults with carcinoid syndrome. When used, “it reduces the frequency of short-acting somatostatin analog rescue therapy” (FDA letter, 2017).
What did the key trials of lanreotide show?
Two randomized, placebo-controlled Phase 3 trials in people support the two newer indications.
CLARINET (tumor control). This double-blind trial enrolled 204 patients with advanced, nonfunctioning, somatostatin receptor-positive grade 1 or 2 tumors (NCT00353496). Tumors arose in the pancreas, midgut, hindgut or an unknown site. Follow-up on treatment lasted up to 96 weeks. The primary endpoint was progression-free survival.
Median progression-free survival was not reached with lanreotide, versus 18.0 months with placebo. The hazard ratio was 0.47 (95% CI 0.30 to 0.73; P<0.001). The estimated 24-month rate was 65.1% with lanreotide and 33.0% with placebo. Overall survival and quality of life did not differ significantly (Caplin et al., 2014).
ELECT (carcinoid syndrome). This 16-week, double-blind trial enrolled 115 patients with carcinoid syndrome (NCT00774930). Patients could use short-acting octreotide as rescue therapy. The primary endpoint was the percentage of days with rescue use. It was 33.7% with lanreotide and 48.5% with placebo, a difference of 14.8 points (P=.017) (Vinik et al., 2016).
What side effects does the lanreotide label list?
The Somatuline Depot label has no boxed warning. Its warnings cover gallstones and their complications, high and low blood sugar, and a slower heart rate. They also cover small drops in thyroid function and fatty stools from poor fat absorption.
The label reports common adverse reactions separately for each condition studied:
- Acromegaly (pooled, N=416): diarrhea 37%, local site reactions 22%, gallstones 20%, abdominal pain 19% and nausea 11%.
- GEP-NETs: abdominal pain 34% (placebo 24%), musculoskeletal pain 19%, vomiting 19% and headache 16%. Local site reactions were 15%, high blood sugar 14%, high blood pressure 14% and gallstones 14% (placebo 7%).
- Carcinoid syndrome: headache 12% (placebo 5%), dizziness 7% (placebo 0%) and muscle spasm 5% (placebo 0%).
In the published CLARINET paper, diarrhea was the most common treatment-related adverse event, at 26% versus 9% with placebo.
What is the regulatory status of lanreotide, and is it used in research?
Lanreotide is a prescription drug. Drugs@FDA lists Somatuline Depot with a “Prescription” marketing status. DailyMed also lists lanreotide acetate labels approved through abbreviated applications, the generic pathway (DailyMed, 2026). A separate lanreotide application from InvaGen was approved on December 17, 2021, and is now listed as discontinued (Drugs@FDA, NDA 215395).
FDA’s Drug Safety Communications page, covering January 2020 to November 9, 2026, lists no communication about lanreotide (FDA, 2026). WADA’s 2026 Prohibited List does not name lanreotide. Our guide to peptides on the 2026 WADA list covers its sections.
Researchers have also tested lanreotide outside its label, in human trials. In the DIPAK 1 trial, 309 adults with later-stage autosomal dominant polycystic kidney disease were randomized. They received lanreotide plus standard care or standard care alone. After 2.5 years, the yearly decline in kidney function did not differ (P=.81). The authors concluded the results do not support lanreotide in later-stage disease (Meijer et al., 2018).
Frequently asked questions about lanreotide
Is lanreotide a peptide?
Yes. The label describes it as a synthetic cyclical octapeptide, meaning a ring-shaped chain of eight amino acids. See types of peptides for how cyclic peptides differ from linear ones.
Is lanreotide the same as octreotide?
No. Both are somatostatin analogs, but they are different molecules with separate labels. In the ELECT trial, short-acting octreotide served as the rescue therapy. Our octreotide guide covers that drug.
Is there a generic version of lanreotide?
Yes. DailyMed lists lanreotide acetate labels marketed under abbreviated new drug applications. They carry the same three indications as Somatuline Depot.
Does lanreotide have a boxed warning?
No. The label lists warnings and precautions, including gallstones and blood sugar changes, but no boxed warning.
Is lanreotide banned in sport?
WADA’s 2026 Prohibited List does not name it. Athletes should check with their anti-doping organization.
What to know now
- What it is: a synthetic cyclic octapeptide analog of somatostatin, 1096.3 g/mol.
- First approval: August 30, 2007, as Somatuline Depot.
- Approved for: acromegaly, certain GEP-NETs (2014) and carcinoid syndrome (2017), as the label states.
- Key evidence: CLARINET (204 patients) and ELECT (115 patients), both human Phase 3 trials.
- Safety: no boxed warning; common reactions include diarrhea, gallstones and abdominal pain.
- Status: prescription only; generic labels exist; not named on the WADA 2026 list.
What we’re watching
A SWOG Phase 3 trial testing whether lanreotide prevents pancreatic fistula after distal pancreatectomy (NCT06807437). It is recruiting 274 patients, with primary completion estimated for April 1, 2029. The LAMPARA Phase 2 study in metastatic pheochromocytoma and paraganglioma (NCT03946527) expects primary completion in March 2027. We also track label revisions on DailyMed.